Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLA expanded access study of nivolumab for malignant non-pleural mesothelioma
jRCT2051220186Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in mesothelioma, sponsored by Ono Pharmaceutical. Primary endpoints: Adverse events, Laboratory tests and 4 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
mesothelioma
Beyond the preview
Go deeper on jRCT2051220186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220186.